Video

Dr. Rao on Improving Methods of Early Detection of Ovarian Cancer

Author(s):

Jianyu Rao, MD

In Partnership With:

Jianyu Rao, MD, professor and chief of Cytopathology, University of California, Los Angeles, discusses improving methods of early detection of ovarian cancer.

Jianyu Rao, MD, professor and chief of Cytopathology, University of California, Los Angeles, discusses improving methods of early detection of ovarian cancer.

In discussions regarding the relationship between genes and histology, physicians and pathologists are trying to determine if there is a way to improve early detection approaches, says Rao. One thing that Rao believes that there must be a better understanding of not only the BRCA genes, but other genes that may be involved in more sporadic cancers. Then, physicians can develop and refine non-invasive approaches like liquid biopsies.

The Hopkins group developed an algorithm to simultaneously analyze proteins and genes together with the hope of improving early detection. However, Rao notes that physicians and pathologists are still waiting to see if it will be clinically useful or not.

Related Videos
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Chirag Shah, MD
Jason A. Mouabbi, MD
Roger Li, MD,
Related Content
Aparna Parikh, MD
July 19th 2024

Rezatapopt Takes Aim at Previously Untargetable p53 Allele to Treat Advanced Solid Tumors

Stephanie L. Graff, MD, director, Breast Oncology, Lifespan Cancer Institute, associate professor, medicine, Brown University; Reshma L. Mahtani, DO, medical oncologist, Miami Cancer Institute, chief, Breast Medical Oncology, Baptist Health’s Wellness and Medical Complex; Kelly E. McCann, MD, PhD, breast medical oncologist, assistant clinical professor, medicine, the University of California, Los Angeles Health David Geffen School of Medicine; Hope S. Rugo, MD, Winterhof Family Endowed Professor in Breast Cancer, the University of California San Francisco (UCSF), professor, medicine, Division of Hematology and Oncology, director, Breast Oncology, director, Clinical Trials Education, director, Cancer Infusion Services, the UCSF Helen Diller Family Comprehensive Cancer Center
April 11th 2024

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

FDA
July 3rd 2024

OncLive’s June Roundup of Key FDA Approvals in Oncology

Zev A. Wainberg, MD, professor, medicine, the University of California, Los Angeles (UCLA), codirector, the UCLA Gastrointestinal Oncology Program
March 11th 2024

FDA Approval Insights: NALIRIFOX in Metastatic Pancreatic Cancer

The FDA has approved a new drug application for Tepylute, a ready-to-dilute formulation to treat breast and ovarian cancers.
June 28th 2024

FDA Approves Tepylute for Breast and Ovarian Cancer Treatment

Edward B. Garon, MD, MS
June 22nd 2024

Garon Discusses the Standing and Future of ADCs, Targeted Therapies in NSCLC